title: Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.
abstract: Randomized controlled trials of patients with non-ST segment elevation acute coronary syndromes have established the superiority of enoxaparin (versus unfractionated heparin) for reducing adverse ischemic outcomes. Furthermore, adjunctive abciximab therapy during percutaneous coronary intervention (PCI) is associated with improved clinical outcomes. Since algorithms for integrating these pharmacotherapies have not been determined, patients undergoing elective PCI were enrolled into 2 distinct and separate studies conducted by the National Investigators Collaborating on Enoxaparin (NICE) study groups (NICE 1 and NICE 4 studies). Patients in NICE 1 were administered enoxaparin 1.0 mg/kg intravenously (without abciximab) and those enrolled in NICE 4 were administered a reduced dose (0.75 mg/kg) of enoxaparin in combination with standard-dose abciximab intravenously during PCI. Bleeding events and ischemic outcomes assessed in-hospital and at 30-days post-PCI were infrequent with either pharmacologic regimen. In the dose regimens studied, enoxaparin with or without abciximab appears to provide safe and effective anticoagulation during PCI. The combination of reduced-dose enoxaparin and abciximab was associated with a low incidence of adverse outcomes (bleeding or ischemic events). Additional studies may be required to establish the relative safety and efficacy of this new adjunctive pharmacologic strategy when compared with the combination of low-dose, weight-adjusted unfractionated heparin and abciximab.
authors: The Carl and Edyth Lindner Center for Research & Education, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219 USA. lindner@fuse.net
authors: D J
authors: DJ
authors: Kereiakes
authors: C
authors: C
authors: Grines
authors: E
authors: E
authors: Fry
authors: P
authors: P
authors: Esente
authors: D
authors: D
authors: Hoppensteadt
authors: M
authors: M
authors: Midei
authors: L
authors: L
authors: Barr
authors: W
authors: W
authors: Matthai
authors: M
authors: M
authors: Todd
authors: T
authors: T
authors: Broderick
authors: R
authors: R
authors: Rubinstein
authors: J
authors: J
authors: Fareed
authors: E
authors: E
authors: Santoian
authors: A
authors: A
authors: Neiderman
authors: B
authors: B
authors: Brodie
authors: J
authors: J
authors: Zidar
authors: J J
authors: JJ
authors: Ferguson
authors: M
authors: M
authors: Cohen
mesh_terms: D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D003327:Coronary Disease / Q000628:therapy*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D017984:Enoxaparin; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab